everal years have passed since the potential for unconjugated monoclonal antibodies (mAbs) to selectively target malignant cells was first described. Although the concept behind serotherapy is theoretically simple, the overall clinical results in these studies have often been disappointing and numerous obstacles have emerged due to the difficulty in penetrating tumor masses, the limited inheren...
